Design Therapeutics, Inc. (DSGN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$12.8M
Cash & Equivalents
$16.4M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$949M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase2 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07024693 | DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy | PHASE2 | Recruiting | 28 |
| NCT06874010 | A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia | PHASE2 | Recruiting | 20 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.